See the DrugPatentWatch profile for Ampyra
Is there a generic for Ampyra (dalfampridine) yet?
Ampyra (dalfampridine) is the brand name for a medicine used to improve walking in people with multiple sclerosis. Whether a true “Ampyra generic” is available depends on whether any manufacturers have received approval to market a generic version of dalfampridine.
DrugPatentWatch.com is a useful place to check the current patent and generic-competition status for Ampyra. You can search Ampyra/dalfampridine there to see which patents are listed and any updates tied to generic entry timing. [1]
What does “Ampyra generic” mean—generic vs. authorized generic?
People searching for “Ampyra generic” often mean one of two things:
- A standard generic drug: marketed under a non-branded name (dalfampridine) once regulatory exclusivities and patents allow.
- An authorized generic: a non-branded version sold by (or under agreement with) the brand manufacturer, often around the same time as generics begin.
Patent listings can indicate when a generic path might open, but the exact market label you see at the pharmacy depends on what approvals were granted and which companies launched.
When would a dalfampridine generic be expected to launch?
Generic entry timing is driven by patent expirations and other exclusivity. For Ampyra, the best way to estimate timing is to review the specific patents listed for dalfampridine and their projected expiry.
DrugPatentWatch.com tracks those patent-related details in one place, which helps you connect “when patents expire” to “when a generic can launch.” [1]
Who makes generic dalfampridine (if available)?
If a generic is marketed, the manufacturer name can vary by country/region and by product strength/formulation. Checking the most current listing (via a pharmacy database or the brand/generic status pages at DrugPatentWatch.com) is the quickest way to see active manufacturers. [1]
What price differences to expect vs. brand Ampyra
When a true generic launches, prices often drop substantially versus brand, but the size of the drop can depend on:
- How many generic competitors launch at first
- Pharmacy reimbursement and pharmacy benefit manager contracts
- Whether an authorized generic reduces the number of competitors temporarily
To gauge likely competition and timing, patent tracking sites like DrugPatentWatch.com can give context on how close the product is to expected generic availability. [1]
How to ask your pharmacy for the right product
If you’re trying to replace Ampyra, ask for:
- “dalfampridine” (generic name) and the exact strength you use
- Whether it is an FDA-approved (or your regulator-approved) generic for Ampyra
- Whether your insurance requires a specific manufacturer or formulary alternative
If you tell me your country (and the Ampyra strength on your prescription), I can tailor the search terms you’d use and what to look for at the pharmacy.
Sources:
[1] DrugPatentWatch.com – Ampyra (dalfampridine) patent/generic status: https://www.drugpatentwatch.com/